Effect of isopsoralen on Smad7 in osteoblastic MC3T3‑E1 cells

Zhang,Huicun; Ta,Na

doi:10.3892/etm.2017.4688

Effect of isopsoralen on Smad7 in osteoblastic MC3T3‑E1 cells

Authors:
- Huicun Zhang
- Na Ta
View Affiliations

Affiliations: Department of Combination of Traditional Chinese and Western Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital University of Medical Sciences, Beijing 100019, P.R. China, Department of Public Health and Risk, China National Health Development Research Center, Beijing 100010, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/etm.2017.4688
Pages: 1561-1567
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The primary pathological change in postmenopausal osteoporosis (PM‑OP) is bone collagen loss caused by estrogen depletion. Osteoblasts synthesize type I collagen, which composes the organic matrix of bone. Although isopsoralen stimulates osteoblastic cell proliferation and differentiation, transforming growth factor (TGF)‑β1 is an important cell signaling factor for stimulating collagen synthesis. To explore the association between isopsoralen and the synthesis of collagen in vitro, the molecular and biological association between isopsoralen and TGF‑β signaling was examined. (CAGA) 12‑luciferase‑reporter gene was used to measure TGF‑β1 signaling activity. Type I collagen was detected by semiquantitative reverse transcription polymerase chain reaction, and mothers against decapentaplegic homolog 7 (Smad7) protein expression levels were analyzed by western blotting. The expression of collagen in MC3T3‑E1 cells stimulated with isopsoralen was significantly upregulated compared with the control groups (P<0.05). Conversely, isopsoralen significantly decreased Smad7 protein expression compared with the control groups (P<0.05). Moreover, it was observed that isopsoralen activates the TGF‑β1 signaling pathway and ultimately promotes collagen synthesis through inhibition of Smad7 protein expression. Therefore, isopsoralen is a potential target for the treatment of PM‑OP.

View Figures

View References

1	Maeda SS and Lazaretti-Castro M: An overview on the treatment of postmenopausal osteoporosis. Arq Bras Endocrinol Metabol. 58:162–171. 2014. View Article : Google Scholar : PubMed/NCBI
2	Janiszewska M, Kulik TB, Dziedzic MA and Żołnierczuk-Kieliszek D: The contemporary look at the problem of recognizing and diagnosing postmenopausal osteoporosis and eliminating the risk of a fall. Prz Menopauzalny. 13:42–47. 2014.PubMed/NCBI
3	Jaha H, Husein D, Ohyama Y, Xu D, Suzuki S, Huang GT and Mochida Y: N-terminal Dentin Sialoprotein fragment induces type I collagen production and upregulates dentinogenesis marker expression in osteoblasts. Biochem Biophys Rep. 6:190–196. 2016.PubMed/NCBI
4	Rydziel S, Varghese S and Canalis E: Transforming growth factor beta1 inhibits collagenase 3 expression by transcriptional and post-transcriptional mechanisms in osteoblast cultures. J Cell Physiol. 70:145–152. 1997. View Article : Google Scholar
5	Katz LH, Li Y, Chen JS, Muñoz NM, Majumdar A, Chen J and Mishra L: Targeting TGF-beta signaling in cancer. Expert Opin Ther Targets. 17:743–760. 2013. View Article : Google Scholar : PubMed/NCBI
6	López-Casillas F, Wrana JL and Massagué J: Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 73:1435–1444. 1993. View Article : Google Scholar : PubMed/NCBI
7	Wrana JL, Attisano L, Wieser R, Ventura F and Massagué J: Mechanism of activation of the TGF-beta receptor. Nature. 370:341–347. 1994. View Article : Google Scholar : PubMed/NCBI
8	Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:465–471. 1997. View Article : Google Scholar : PubMed/NCBI
9	Derynck R, Zhang Y and Feng XH: Smads: Transcriptional activators of TGF-beta responses. Cell. 95:737–740. 1998. View Article : Google Scholar : PubMed/NCBI
10	Wu M, Chen G and Li YP: TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 4:160092016. View Article : Google Scholar : PubMed/NCBI
11	Steiner RD, Adsit J and Basel D: COL1A1/2-related osteogenesis imperfectaGeneReviews. Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH and Stephens K: University of Washington; Seattle, WA: 2005
12	Saito M and Marumo K: Collagen cross-links as a determinant of bone quality: A possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 21:195–214. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gelse K, Pöschl E and Avinger T: Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev. 55:1531–1546. 2003. View Article : Google Scholar : PubMed/NCBI
14	Chen G, Deng C and Li YP: TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 8:272–288. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mukasa C, Nomura M, Tanaka T, Tanaka K, Nishi Y, Okabe T, Goto K, Yanase T and Nawata H: Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulosa cell-like human granulose (KGN) cells. Endocrinology. 144:1603–1611. 2003. View Article : Google Scholar : PubMed/NCBI
16	Arjmandi BH: The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. J Am Coll Nutr. 20 5 Suppl:398S–402S, 417S-420S. 2001. View Article : Google Scholar : PubMed/NCBI
17	Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW and Haussler MR: Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 241:81–84. 1988. View Article : Google Scholar : PubMed/NCBI
18	Majeska RJ, Ryaby JT and Einhorn TA: Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg Am. 76:713–721. 1994. View Article : Google Scholar : PubMed/NCBI
19	Benz DJ, Haussler MR and Komm BS: Estrogen binding and estrogenic responses in normal human osteoblast-like cells. J Bone Miner Res. 6:531–541. 1991. View Article : Google Scholar : PubMed/NCBI
20	Virk-Baker MK, Nagy TR and Barnes S: Role of phytoestrogens in cancer therapy. Planta Med. 76:1132–1142. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yamaguchi M and Sugimoto E: Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T3-E1 cells: Activation of aminoacyl-tRNA synthetase. Mol Cell Biochem. 214:97–102. 2000. View Article : Google Scholar : PubMed/NCBI
22	Wu J, Wang XX, Takasaki M, Ohta A, Higuchi M and Ishimi Y: Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice. J Bone Miner Res. 16:1829–1836. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zhao LH, Wu MH and Xiang BR: Analysis of Psoralea corylifolia L. fruits in different regions. Chem Pharm Bull (Tokyo). 53:1054–1057. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen X, Kong L, Su X, Pan C, Ye M and Zou H: Integration of ion-exchange chromatography fractionation with reversed-phase liquid chromatography-atmospheric pressure chemical ionization mass spectrometer and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for isolation and identification of compounds in Psoralea corylifolia. J Chromatogr A. 1089:87–100. 2005. View Article : Google Scholar : PubMed/NCBI
25	Wang D, Yang G, Engelhardt H and Zhang H: Micellar electrokinetic capillary chromatography of psoralen and isopsoralen. Electrophoresis. 20:1895–1899. 1999. View Article : Google Scholar : PubMed/NCBI
26	Xin D, Wang H, Yang J, Su YF, Fan GW, Wang YF, Zhu Y and Gao XM: Phytoestrogens from Psoralea corylifolia reveal estrogen receptor-subtype selectivity. Phytomedicine. 17:126–131. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ming LG, Cheng KM, Ge BF, Ma HP and Zai YK: Effect of isopsoralen on the proliferation and differentiate of osteoblasts in vitro. Zhong Yao Cai. 34:404–408. 2011.(In Chinese). PubMed/NCBI
28	He Z, Feng L, Zhang X, Geng Y, Parodi DA, Suarez-Quian C and Dym M: Expression of Col1a1, Col1a2 and procollagen I in germ cells of immature and adult mouse testis. Reproduction. 130:333–341. 2005. View Article : Google Scholar : PubMed/NCBI
29	Lanyon L, Armstrong V, Ong D, Zaman G and Price J: Is estrogen receptor alpha key to controlling bones' resistance to fracture? J Endocrinol. 182:183–191. 2004. View Article : Google Scholar : PubMed/NCBI
30	László A: Postmenopausal osteoporosis. Orv Hetil. 145:3–13. 2004.(In Hungarian). PubMed/NCBI
31	Gallagher JC: Moderation of the daily dose of HRT: Prevention of osteoporosis. Maturitas. 33 Suppl 1:S57–S63. 1999. View Article : Google Scholar : PubMed/NCBI
32	Pardini D: Menopausal hormone therapy. Arq Bras Endocrinol Metabol. 51:938–942. 2007.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
33	Prelevic GM, Kocjan T and Markou A: Hormone replacement therapy in postmenopausal women. Minerva Endocrinol. 30:27–36. 2005.PubMed/NCBI
34	Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R and Gennari C: The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res. 12:624–631. 1997. View Article : Google Scholar : PubMed/NCBI
35	Fitzpatrick LA: Estrogen therapy for postmenopausal osteoporosis. Arq Bras Endocrinol Metabol. 50:705–719. 2006. View Article : Google Scholar : PubMed/NCBI
36	Dören M and Samsioe G: Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995. Hum Reprod Update. 6:419–426. 2000. View Article : Google Scholar : PubMed/NCBI
37	Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kröger H and Saarikoski S: Hormone replacement therapy and mortality in 52- to 70-year-old women: The kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol. 154:101–107. 2006. View Article : Google Scholar : PubMed/NCBI
38	Nikander E, Metsä-Heikkilä M, Ylikorkala O and Tiitinen A: Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrnol Metab. 89:1207–1212. 2004. View Article : Google Scholar
39	Deady J: Clinical monograph: Hormone replacement therapy. J Manag Care Pharm. 10:33–47. 2004.PubMed/NCBI
40	Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS and Ferguson MW: Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med. 3:1209–1215. 1997. View Article : Google Scholar : PubMed/NCBI
41	Bonewald LF and Mundy GR: Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1–276. 1990.
42	Noda M and Camilliere JJ: In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology. 124:2991–2994. 1989. View Article : Google Scholar : PubMed/NCBI
43	Marie P: Growth factors and bone formation in osteoporosis: Roles for IGF-I and TGF-beta. Rev Rhum Engl Ed. 64:44–53. 1997.PubMed/NCBI
44	Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A and Ikeda K: Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese wome. J Bone Miner Res. 13:1569–1576. 1998. View Article : Google Scholar : PubMed/NCBI
45	Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091–3100. 1998. View Article : Google Scholar : PubMed/NCBI
46	Taxvig C, Elleby A, Sonne-Hansen K, Bonefeld-Jørgensen EC, Vinggaard AM, Lykkesfeldt AE and Nellemann C: Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutr Cancer. 62:122–131. 2010. View Article : Google Scholar : PubMed/NCBI
47	Estai MA, Suhaimi F, Das S, Shuid AN, Mohamed Z and Soelaiman IN: Expression of TGF-β1 in the blood during fracture repair in an estrogen-deficient rat model. Clinics (Sao Paulo). 66:2113–2119. 2011. View Article : Google Scholar : PubMed/NCBI
48	Limer JL and Speirs V: Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 6:119–127. 2004. View Article : Google Scholar : PubMed/NCBI
49	Knight DC and Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol. 87:897–904. 1996.PubMed/NCBI
50	Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH and Wrana JL: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell. 6:1365–1375. 2000. View Article : Google Scholar : PubMed/NCBI
51	Souchelnytskyi S, Nakayama T, Nakao A, Morén A, Heldin CH, Christian JL and ten Dijke P: Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors. J Biol Chem. 273:25364–25370. 1998. View Article : Google Scholar : PubMed/NCBI
52	Peleg S, Uskokovic M, Ahene A, Vickery B and Avnur Z: Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology. 143:1625–1636. 2002. View Article : Google Scholar : PubMed/NCBI
53	Bord S, Beavan S, Ireland D, Horner A and Compston JE: Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: Role of locally produced growth factors. Bone. 29:216–222. 2001. View Article : Google Scholar : PubMed/NCBI